



Qty: 50 µg/100 µl
Mouse anti-p300
Catalog No. 33-7600
Lot No.

Mouse anti-p300

FORM

This monoclonal antibody is highly purified from mouse ascites by protein A chromatography. The antibody is supplied as a 100 µl aliquot at a concentration of 0.5 mg/ml in PBS, pH 7.4, containing 0.1% sodium azide.

CLONE: NM-11 **ISOTYPE:** IgG₁

IMMUNOGEN

Recombinant human p300 protein.

SPECIFICITY

This antibody reacts with human p300. It does not react with mouse or rat p300. The epitope bound by this antibody has not been determined.

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate dilutions will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. We recommend the following ranges as starting points for this product.

Application	Amount	Positive Control
Immunofluorescence	1-5 µg/ml	A431, HeLa or ML-1 cells
Immunohistochemistry (frozen)	not tested	
Immunohistochemistry (staining of formalin fixed, paraffin embedded tissue requires HIER* pretreatment)	1-5 µg/ml	any tissue
Immunoprecipitation ⁽¹¹⁾ (autoradiographic detection)	1 µg/sample	A431, HeLa or ML-1 cells
Western Blotting (chemiluminescence detection)	1 µg/ml	A431, HeLa or ML-1 cells

* HIER: Heat induced epitope retrieval. Contact Invitrogen Technical Service for protocol

STORAGE

Store at 2-8°C for up to one month. Store at -20°C for long term storage. Avoid repeated freezing and thawing.

BACKGROUND

p300 is a nuclear phosphoprotein which was originally shown to specifically bind to adenovirus E1A protein⁽¹⁻³⁾. The binding of p300 to E1A occurs in the conserved region 1 (CR1) of E1A at a site which is close to but non-overlapping with that for the Rb family of proteins including p105 and p107^(4,5). p300 has been shown to bind to the extreme N-terminal region requiring the presence of positively charged residues at positions 2 and 3 of E1A via a zinc-finger motif in the C-terminal portion of p300⁽⁵⁻⁸⁾. While the binding of p300 and Rb to E1A is independent, it has been shown that upon binding, E1A mediates the physical contact between the two proteins⁽⁵⁾. The p300 protein is actively phosphorylated in both quiescent and proliferating cells however the amount of phosphorylation increases during progression from late G1 into M phase of the cell cycle^(1,9). In addition to the demonstrated binding of p300 to E1A it has also been shown to bind to other molecules including DNA (in a site specific manner) and to components of the TATA binding protein complexes (TBP)^(10,11). The TBP complex association is most likely with TFUD and occurs in a protein-protein dependent rather than DNA dependent manner and, in such a complex, p300 functions as a co-activator of transcription^(11,12). CPB is similar both structurally and functionally to p300.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI337600

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

REFERENCES

1. Yee, S. and Branton, P., *Virology* 147:142-153 (1985).
2. Egan, C., et al., *Mol. Cell Biol.* 8:3995-3959 (1988).
3. Yaciuk, P. and Moran, W., *Mol. Cell Biol.* 11:5389:5397 (1991).
4. Shisler, L., et al., *J. Virol.* 70:68-77 (1996).
5. Wang, H.G., et al., *J. Virol.* 69:7917-7924 (1995).
6. Wang, H.G., et al., *J. Virol.* 67:476-488 (1993).
7. Howe, J.A. and Bayley, S.T., *Virology* 186:15-24 (1992).
8. Eckner, R., et al., *Genes Dev.* 8:869-884 (1994).
9. Banerjee, A.C., et al., *Oncogene* 9:1733-1737 (1994).
10. Rikitake, Y. and Moran, E., *Mol. Cell Biol.* 11:2826-2836 (1992).
11. Abraham, S.E., et al., *Oncogene* 8:1639-1647 (1993).

RELATED PRODUCTS

<i>Product</i>	<i>Conjugate</i>	<i>Cat. No.</i>
Goat anti-Mouse IgG (H+L) (ZyMax™ Grade)	purified	81-6500
	FITC	81-6511
	TRITC	81-6514
	Cy™3	81-6515
	Cy™5	81-6516
	HRP	81-6520
	AP	81-6522
	Biotin	81-6540
rec-Protein G	Sepharose® 4B	10-1241
Protein A	Sepharose® 4B	10-1041

Zymed® and ZyMAX™ are trademarks of Zymed Laboratories Inc. Cy™ is a trademark of Amersham Life Sciences, Inc. Sepharose® is a registered trademark of Pharmacia LKB.

For Research Use Only

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI337600

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.